ZD1839 (Iressa) Modifies the Activity of Key Enzymes Linked to Fluoropyrimidine Activity: Rational Basis for a New Combination Therapy with Capecitabine

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4735-4742

  Magné, Nicolas ^a   Fischel, Jean Louis ^a   Dubreuil, Alain ^a   Formento, Patricia ^a   Ciccolini, Joseph ^b   Formento, Jean Louis ^a   Tiffon, Céline ^a   Renée, Nicole ^a   Marchetti, Sandrine ^a   Etienne, Marie Christine ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PYRIMIDINE METABOLISM;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DNA PRIMERS; FLOXURIDINE; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, CHEMICAL; POLYMERASE CHAIN REACTION; PYRIMIDINES; QUINAZOLINES; RNA; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 10744230754     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Pivot, X., Chamorey, E., Guardiola, E., Magné, N., Thyss, A., Otto, J., Giroux, B., Mouri, Z., Schneider, M., and Milano, G. Phase I accelerated dose escalation and pharmacokinetic (PK) study of capecitabine and cisplatin (CP) in head and neck cancer patients. Proc. Am. Soc. Clin. Oncol., 21: 108a, 2002.
2. Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., McKendric, J., Maroun, J., Marshall, J., Osterwalder, B., Perez-Manga, G., Rosso, R., Rougier, P., Schilsky, R. L., and Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol., 13: 566-575, 2002.
3. Borner, M. M., Dietrich, D., Stupp, R., Morant, R., Honegger, H., Wernli, M., Herrmann, R., Pestalozzi, B. C., Saletti, P., Hanselmann, S., Muller, S., Brauchli, P., Castiglione-Gertsch, M., Goldhirsch, A., and Roth, A. D. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J. Clin. Oncol., 20: 1759-1766, 2002.
4. Cassata, A., Procoplo, G., Alu, M., Ferrari, L., Ferrario, E., Beretta, E., Longarini, R., Busto, G., De Candis, D., and Bajetta, E. Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer. Tumori, 87: 364-371, 2001.
5. Talbot, D. C., Moiseyenko, V., Van Belle, S., O'Reilly, S. M., Alba Conejo, E., Ackland, S., Eisenberg, P., Melnychuk, D., Pienkowski, T., Burger, H. U., Laws, S., and Osterwalder, B. Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br. J. Cancer, 86: 1367-1372, 2002.
6. O'Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J. P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W. Y., Mauriac, L., Twelves, C., Van Hazel, G., Verma, S., and Leonard, R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol., 20: 2812-2823, 2002.
7. Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., and Ishitsuka, H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer, 34: 1274-1281, 1998.
8. Diasio, R. B., and Harris, B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
9. Beck, A., Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Renée, N., and Milano, G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer, 30A: 1517-1522, 1994.
10. Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renée, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol., 13: 1663-1670, 1995.
11. Ishikawa, T., Sekiguchi, F., Fukase, Y., Sawada, N., and Ishitsuka, H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res., 58: 685-690, 1998.
12. Nishimura, G., Terada, I., Kobayashi, T., Ninomiya, I., Kitagawa, H., Fushida, S., Fujimura, T., Kayahara, M., Shimizu, K., Ohta, T., and Miwa, K. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol. Rep., 9: 479-482, 2002.
13. Sawada, N., Ishikawa, T., Fukase, Y., Nishida, M., Yoshikubo, T., and Ishitsuka, H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin. Cancer Res., 4: 1013-1019, 1998.
14. Ishitsuka, H. Capecitabine: preclinical pharmacology studies. Invest. New Drugs, 18: 343-354, 2000.
15. Nadella, P., Shapiro, C., Otterson, G. A., Hauger, M., Erdal, S., Kraut, E., Clinton, S., Shah, M., Stanek, M., Monk, P., and Villalona-Calero, M. A. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J. Clin. Oncol., 20: 2616-2623, 2002.
16. Kubota, Y., Miura, T., Moriyama, M., Noguchi, S., Matsuzaki, J., Takebayashi, S., and Hosaka, M. Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. Clin. Cancer Res., 3: 973-976, 1997.
17. Kitabatake, T., Kojima, K., Fukasawa, M., Beppu, T., and Futagawa, S. Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer. Surg. Today, 32: 322-328, 2002.
18. Yarden, Y. The EGFR family and its ligands in human cancer; signalling mechanisms and therapeutic opportunities. Eur. J. Cancer., 37 (Suppl 4): S3-S8, 2001.
19. Baselga, J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur. J. Cancer, 37 (Suppl 4): S16-S22, 2001.
20. Dassonville, O., Formento, J. L., Francoual, M., Ramaioli, A., Santini, J., Schneider, M., Demard, F., and Milano, G. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol., 11: 1873-1878, 1993.
21. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
22. Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., and Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res., 6: 4885-4892, 2000.
23. Magné, N., Fischel, J. L., Dubreuil, A., Formento, P., Poupon, M. F., Laurent-Puig, P., and Milano, G. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br. J. Cancer, 86: 1518-1523, 2002.
24. Magné, N., Fischel, J. L., Dubreuil, A., Formento, P., Marcié, S., Lagrange, J. L., and Milano, G. Sequence-dependent effects of ZD1839 ("Iressa") in combination with cytotoxic treatment in human head and neck cancer. Br. J. Cancer, 86: 819-827, 2002.
25. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
26. Chou, T., and Talalay, P. Quantitative analysis of dose-effects relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
27. Spears, C. P., and Gustavsson, B. G. Methods for thymidylate synthase pharmacodynamics: serial biopsy, free and total TS, FdUMP and dUMP, and H4PteGlu and CH2-H4PteGlu assays. Adv. Exp. Med. Biol., 244: 97-106, 1988.
28. Harris, B. E., Song, R., Soong, S. J., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
29. Milano, G., Etienne, M. C., Cassuto-Viguier, E., Thyss, A., Santini, J., Frenay, M., Renée, N., Schneider, M., and Demard, F. Influence of sex and age on fluorouracil clearance. J. Clin. Oncol., 7: 1171-1175. 1992.
30. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
31. Ciccolini, J., Peillard, L., Evrard, A., Cuq, P., Aubert, C., Pelegrin, A., Formento, P., Milano, G., and Catalin, J. Enhanced antitumor activity of 5-fluorouracil in combination with 2′-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. Clin Cancer Res., 6: 1529-1535, 2000.
32. Endo, M., Shinbori, N., Fukase, Y., Sawada, N., Ishikawa, T., Ishitsuka, H., and Tanaka, Y. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluoropyrimidine by cyclophosphamide in mammary tumor models. Int. J. Cancer, 83: 127-134, 1999.
33. Sawada, N., Ishikawa, T., Sekiguchi, F., Tanaka, Y., and Ishitsuka, H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin. Cancer Res., 5: 2948-2953, 1999.
34. Grem, J. L., Danenberg, K. D., Behan, K., Parr, A., Young, L., Danenberg, P. V., Nguyen, D., Drake, J., Monks, A., and Allegra, C. J. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anti-cancer Drug Screen. Clin. Cancer Res., 7: 999-1009, 2001.
35. Bjarnason, G. A., Jordan, R. C., Wood, P. A., Li, Q., Lincoln, D. W., Sothern, R. B., Hrushesky, W. J., and Ben-David, Y. Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am. J. Pathol., 158: 1793-1801, 2001.
36. Longo, G. S., Izzo, J., Gorlick, R., Banerjee, D., Jhanwar, S. C., and Bertino, J. R. Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidilate synthase. Oncol. Res., 12: 309-314, 2000.
37. Liu, J., Schmitz, J. C., Lin, X., Tai, N., Yan, W., Farrell, M., Bailly, M., Chen, T., and Chu, E. Thymidylate synthase as a translational regulator of cellular gene expression. Biochim. Biophys. Acta, 1587: 174-182, 2002.
38. Longley, D. B., Ferguson, P. R., Boyer, J., Latif, T., Lynch, M., Maxwell, P., Harkin, D. P., and Johnston, P. G. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin. Cancer Res., 7: 3533-3539, 2001.
39. Marchetti, S., Chazal, M., Dubreuil, A., Fischel, J. L., Etienne, M. C., and Milano, G. Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis. Br. J. Cancer, 85: 439-445, 2001.
40. Ciccolini, J., Cuq, P., Evrard, A., Giacometti, S., Pelegrin, A., Aubert, C., Cano, J. P., and Iliadis, A. Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol. Cancer Ther., 1: 133-139, 2001.
41. Ciccolini, J., Fina, F., Bezulier, K., Giacometti, S., Roussel, M., Evrard, A., Cuq, P., Romain, S., Martin, P. M., and Aubert, C. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol. Cancer Ther., 1: 923-927, 2002.